RecruitingNot ApplicableNCT06690736

Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases

Sponsor

Tianjin Medical University

Enrollment

200 participants

Start Date

Mar 1, 2022

Study Type

INTERVENTIONAL

Conditions

Metastasis Tumor Positron Emission Tomography CXCR4-related Disease

Summary

To evaluate the potential usefulness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying CXCR4 PET/CT Imaging for people with cxcr4-related disease, metastasis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTCXCR4 PET/CT Imaging

Each subject receive a single intravenous injection of 68Ga/18F-Pentixafor/Pentixather, and undergo PET/CT imaging within the specificed time.

Locations(3)

The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui, China

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06690736

Related Trials

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

NCT0686327281 locations

Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients

NCT066909702 locations